236 related articles for article (PubMed ID: 19563061)
41. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
42. [Clinical study of the low dose oral contraceptive novynette].
Uchikova E; Milchev N
Akush Ginekol (Sofiia); 2003; 42(4):15-6. PubMed ID: 14577362
[TBL] [Abstract][Full Text] [Related]
43. [Clinical study of two monophase oral contraceptives with desogestrel].
Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
[TBL] [Abstract][Full Text] [Related]
44. Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone).
Mohamed AM; El-Sherbiny WS; Mostafa WA
Int J Gynaecol Obstet; 2011 Aug; 114(2):145-8. PubMed ID: 21669426
[TBL] [Abstract][Full Text] [Related]
45. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
[TBL] [Abstract][Full Text] [Related]
46. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women.
Suthipongse W; Taneepanichskul S
Contraception; 2004 Jan; 69(1):23-6. PubMed ID: 14720615
[TBL] [Abstract][Full Text] [Related]
47. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
Keam SJ; Wagstaff AJ
Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
[TBL] [Abstract][Full Text] [Related]
48. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
Stone S
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():117-21. PubMed ID: 8260969
[TBL] [Abstract][Full Text] [Related]
49. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
[TBL] [Abstract][Full Text] [Related]
50. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
Witjes H; Creinin MD; Sundström-Poromaa I; Martin Nguyen A; Korver T
Eur J Contracept Reprod Health Care; 2015; 20(4):296-307. PubMed ID: 25712537
[TBL] [Abstract][Full Text] [Related]
51. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
52. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone.
Shoupe D
Obstet Gynecol; 1994 May; 83(5 Pt 1):679-85. PubMed ID: 8164925
[TBL] [Abstract][Full Text] [Related]
53. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol.
Winkler UH; Ferguson H; Mulders JA
Contraception; 2004 Jun; 69(6):469-76. PubMed ID: 15157791
[TBL] [Abstract][Full Text] [Related]
54. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
[TBL] [Abstract][Full Text] [Related]
55. Drospirenone/ethinyl estradiol.
Rapkin AJ; Sorger SN; Winer SA
Drugs Today (Barc); 2008 Feb; 44(2):133-45. PubMed ID: 18389090
[TBL] [Abstract][Full Text] [Related]
56. Use of an oral contraceptive containing drospirenone in an extended regimen.
Sillem M; Schneidereit R; Heithecker R; Mueck AO
Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
[TBL] [Abstract][Full Text] [Related]
57. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol.
Duijkers IJ; Klipping C; Grob P; Korver T
Eur J Contracept Reprod Health Care; 2010 Oct; 15(5):314-25. PubMed ID: 20695770
[TBL] [Abstract][Full Text] [Related]
58. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
Mansour D
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
[TBL] [Abstract][Full Text] [Related]
59. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
Marr J; Heinemann K; Kunz M; Rapkin A
Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
[TBL] [Abstract][Full Text] [Related]
60. Recent innovations in oral contraception.
Cremer M; Phan-Weston S; Jacobs A
Semin Reprod Med; 2010 Mar; 28(2):140-6. PubMed ID: 20391327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]